ESLAW
Estrella Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.08
+3.33%Next report
Analyst consensus
- Next report date
- Dec 2, 2026
- EPS estimate
- -$0.08
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.05
- EPS estimate
- -$0.09
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +51.6%
- Revenue beats (12Q)
- —
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Dec 2, 2026